Orthopedic care is increasingly focused not only on relieving symptoms but on delivering durable outcomes that stand up over time. That shift is creating greater interest in regenerative approaches designed to restore damaged tissue rather than simply address the immediate effects of injury. Regentis Biomaterials is advancing this approach with GelrinC, a degradable hydrogel implant designed to support the regeneration of durable cartilage in the knee.
Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time? One company pursuing this approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions with an initial focus on orthopedic applications. Its technology is built around the… Read More>>
The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT. This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN. Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
The story was distributed through BioMedWire (“BMW”), a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.BioMedWire.com.
